We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Exicure

News List

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008) drugs
August 10, 2021
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785).
Ipsen and Exicure to develop therapies for neurodegenerative disorders pharmaceutical-technology
August 04, 2021
Ipsen and Exicure have entered an exclusive partnership agreement for the research, development and marketing of new spherical nucleic acids (SNAs) for the potential treatment of Huntington’s disease and Angelman syndrome.
Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases pharmafocusasia
February 21, 2019
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs....
Exicure Announces Positive Phase 1 Results for Lead Immuno-Oncology Asset americanpharmaceuticalreview
September 21, 2018
Exicure announced Phase 1 results for AST-008, an SNA consisting of toll-like receptor 9 (TLR9) agonists designed for immuno-oncology applications.